Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors

1. A method for forming a pharmaceutical composition, comprising:

(a) forming a molten mixture comprising a cholesteryl ester transfer protein inhibitor and a concentration-enhancing polymer;

(b) cooling said mixture to form a solid amorphous dispersion comprising said cholesteryl ester transfer protein inhibitor and said concentration-enhancing polymer; and

(c) providing a sufficient-amount of said concentration-enhancing polymer in said mixture so that said solid amorphous dispersion provides a maximum concentration of said cholesteryl ester transfer protein inhibitor in a use environment that is at least 10-fold the equilibrium concentration provided by a control composition consisting essentially of an equivalent amount of said cholesteryl ester transfer protein inhibitor but with no concentration-enhancing polymer,

wherein said cholesteryl ester transfer protein inhibitor has a Clog P greater than 4 and a solubility in aqueous solution in the absence of said concentration-enhancing polymer of less than 10 μg/ml at any pH of from 1 to 8, at about 22° C.,

and wherein said concentration-enhancing polymer is selected from vinyl polymers and copolymers having substituents of hydroxyl, alkylacyloxy, or cyclicamido; polyvinyl alcohols that have at least a portion of their repeat units in the unhydrolyzed (vinyl acetate) form; polyvinyl alcohol polyvinyl acetate copolymers; polyvinyl pyrrolidone; poloxamers; polyethylene polyvinyl alcohol copolymers, carboxylic acid functionalized polymethacrylates and carboxylic acid functionalized polyacrylates; amine-functionalized polyacrylates and polymethacrylates; proteins; and carboxylic acid functionalized starches, hydroxypropyl methyl cellulose acetate, hydroxypropyl methyl cellulose, hydroxypropyl cellulose, methyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose acetate, hydroxyethyl ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate, hydroxypropyl methyl cellulose succinate, hydroxypropyl cellulose acetate succinate, hydroxyethyl methyl cellulose succinate, hydroxyethyl cellulose acetate succinate, hydroxypropyl methyl cellulose phthalate, hydroxyethyl methyl cellulose acetate succinate, hydroxyethyl methyl cellulose acetate phthalate, carboxyethyl cellulose, carboxymethyl cellulose, carboxymethylethyl cellulose, cellulose acetate phthalate, methyl cellulose acetate phthalate, ethyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate, hydroxypropyl methyl cellulose acetate phthalate, hydroxypropyl cellulose acetate phthalate succinate, hydroxypropyl methyl cellulose acetate succinate phthalate, hydroxypropyl methyl cellulose succinate phthalate, cellulose propionate phthalate, hydroxypropyl cellulose butyrate phthalate, cellulose acetate trimellitate, methyl cellulose acetate trimellitate, ethyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate, hydroxypropyl methyl cellulose acetate trimellitate, hydroxypropyl cellulose acetate trimellitate succinate, cellulose propionate trimellitate, cellulose butyrate trimellitate, cellulose acetate terephthalate, cellulose acetate isophthalate, cellulose acetate pyridinedicarboxylate, salicylic acid cellulose acetate, hydroxypropyl salicylic acid cellulose acetate, ethylbenzoic acid cellulose acetate, hydroxypropyl ethylbenzoic acid cellulose acetate, ethyl phthalic acid cellulose acetate, ethyl nicotinic acid cellulose acetate, and ethyl picolinic acid cellulose acetate.

2. The method of claim 1 , further comprising the step of adding an excipient to reduce the temperature required to form said molten mixture.

3. The method of claim 1 , further comprising the step of mixing said molten mixture so that said molten mixture is substantially homogeneous.

4. The method of claim 1 wherein said molten mixture is formed by melting said concentration-enhancing polymer and adding said cholesteryl ester transfer protein inhibitor to said concentration-enhancing polymer.

5. The method of claim 1 wherein said molten mixture is formed by melting said cholesteryl ester transfer protein inhibitor and adding said concentration-enhancing polymer to said cholesteryl ester transfer protein inhibitor.

6. The method of claim 1 wherein said molten mixture is formed by mixing said cholesteryl ester transfer protein inhibitor and said concentration-enhancing polymer together to form a solid blend and heating said solid blend.

7. The method of claim 6 wherein said solid blend is heated in an extruder.

8. The method of claim 1 wherein said cholesteryl ester transfer protein inhibitor is substantially amorphous and said dispersion is substantially homogeneous.

9. The product produced by the method of any one of claims 1 - 6 .

10. The product of claim 9 wherein said dispersion has a single glass transition temperature.

11. The product of claim 9 which provides in a use environment an area under the concentration versus time curve for any period of at least 90 minutes between the time of introduction into the use environment and about 270 minutes following introduction to the use environment that is at least about 5-fold that of a control composition.

12. The product of claim 9 which provides a relative bioavailability that is at least 4-fold relative to said control composition.

13. The product of claim 9 wherein the cholesteryl ester transfer protein inhibitor has a dose-to-aqueous-solubility ratio of at least 1,000 ml.

14. The method of claim 1 wherein said cholesteryl ester transfer protein inhibitor is 3-[[3-(4-chloro-3-ethylphenoxy)phenyl][[3-(1,1,2,2-tetrafluoroethoxy)phenyl]-methyl]amino]-1,1,1-trifluoro-2-propanol.

15. The method of claim 1 wherein said molten mixture of step (a) is formed in an extruder.

16. The method of claim 1 wherein said cholesteryl ester transfer protein inhibitor is propanethioic acid, 2-methyl-S-[2[[[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino]phenyl]ester.